AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10766405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemia (HTG)
Number of subjects: 163
Study 8829166 — intervention group
Group type: EXPERIMENTAL
Intervention: Death education (three two-hour didactic/experiential classes)
Number of subjects: 28
Study 8829166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 8829166 — intervention group
Group type: EXPERIMENTAL
Intervention: Death education
Number of subjects: 28
Study 1573544 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid treatment for 30, 60, 120, or 240 seconds
Number of subjects: 20
Study 1573544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl treatment for 30, 60, 120, or 240 seconds
Number of subjects: 20
Study 1573544 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 20
Study 3933330 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V given twice daily (250 mg for ten days)
Number of subjects: 99
Study 3933330 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V given three times daily (250 mg for ten days)
Number of subjects: 99
Study 30805104 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 63
Study 30805104 — intervention group
Group type: COMPARATOR
Intervention: Standard classroom
Number of subjects: 63
Study 29031769 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 19
Study 29031769 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 19
Study 26957322 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary school garden, nutrition and WASH intervention
Number of subjects: 1144
Study 26957322 — intervention group
Group type: COMPARATOR
Intervention: Control (no interventions)
Number of subjects: 1144
Study 24619932 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2456302 (2-60 mg single doses)
Number of subjects: 0
Study 24619932 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2456302 (2, 10, and 35 mg multiple doses)
Number of subjects: 0
Study 24619932 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2456302 co-administered with ethanol
Number of subjects: 0
Study 24619932 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2456302
Number of subjects: 0
Study 24619932 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (in presence of LY2456302)
Number of subjects: 0
Study 22454189 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐month CHW intervention
Number of subjects: 360
Study 22454189 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (educational materials mailed at 4‐month intervals, preceded by phone calls)
Number of subjects: 360
Study 20076848 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily for five days
Number of subjects: 56
Study 20076848 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily for five days
Number of subjects: 56
Study 17441658 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated total knee arthroplasty using a computed navigation system
Number of subjects: 42
Study 17441658 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty technique
Number of subjects: 42
Study 16254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline systolic BP or diastolic BP
Number of subjects: 615
Study 16254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower within-patient 0- to 72-hour average systolic BP or diastolic BP
Number of subjects: 615
Study 16254220 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced variability of 0- to 72-hour diastolic BP profile
Number of subjects: 615
Study 12216025 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow cooling device applied over the surgical dressing immediately postoperatively
Number of subjects: 30
Study 12216025 — intervention group
Group type: COMPARATOR
Intervention: No cooling device (control TKA)
Number of subjects: 30
Study 9502680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-spray thrombolysis with high-dose urokinase
Number of subjects: 24
Study 9502680 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion thrombolysis with high-dose urokinase
Number of subjects: 24
Study 7633701 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (2 mg bolus followed by 2 mg every 4 min)
Number of subjects: 145
Study 7633701 — intervention group
Group type: COMPARATOR
Intervention: Methoxamine (40 mg bolus followed after 4 min by 40 mg)
Number of subjects: 145
Study 7633701 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 145
Study 7633701 — intervention group
Group type: COMPARATOR
Intervention: Methoxamine
Number of subjects: 145
Study 2520343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, daily dose 4 x 0.1 mg for 6 weeks
Number of subjects: 14
Study 2520343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate 15 mg at bedtime
Number of subjects: 40
Study 20284 — intervention group
Group type: COMPARATOR
Intervention: Diazepam thrice daily
Number of subjects: 40
Study 31794928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 334
Study 31794928 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 334
Study 29772928 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical carepath for obese pregnant women
Number of subjects: 189
Study 29772928 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 189
Study 27762648 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 tumors (Luminal A-like)
Number of subjects: 671
Study 27762648 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 tumors (Luminal A-like)
Number of subjects: 671
Study 27762648 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 tumors
Number of subjects: 671
Study 27762648 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 tumors (Luminal B-like)
Number of subjects: 671
Study 27762648 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 tumors (Luminal B-like)
Number of subjects: 671
Study 26112224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led psychoeducational intervention for 36 weeks
Number of subjects: 120
Study 26112224 — intervention group
Group type: COMPARATOR
Intervention: Augmented usual care
Number of subjects: 120
Study 23583056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate monotherapy for ≥6 months
Number of subjects: 117
Study 21713025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin treatment with MIC ≤0.125 µg/mL
Number of subjects: 540
Study 21713025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin treatment with MIC between 0.25 and 0.50 µg/mL
Number of subjects: 540
Study 21713025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin treatment with MIC 1.00 µg/mL
Number of subjects: 540
Study 21713025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin treatment with MIC ≥0.25 µg/mL
Number of subjects: 540
Study 19903189 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 240
Study 19903189 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 240
Study 19903189 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone + Propranolol
Number of subjects: 240
Study 16689844 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) catheter ablation
Number of subjects: 142
Study 15542798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with four gp100‐ and tyrosinase‐derived peptides plus low-dose IL-2 administered daily beginning day 28 (group 2)
Number of subjects: 40
Study 15542798 — intervention group
Group type: COMPARATOR
Intervention: Vaccination with four gp100‐ and tyrosinase‐derived peptides plus low-dose IL-2 administered daily beginning day 7 (group 1)
Number of subjects: 40
Study 15542798 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 40
Study 15542798 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (group 2)
Number of subjects: 40
Study 10674497 — intervention group
Group type: EXPERIMENTAL
Intervention: 902 MHz electromagnetic field emitted by cellular telephones
Number of subjects: 48
Study 10674497 — intervention group
Group type: COMPARATOR
Intervention: No exposure to the electromagnetic field
Number of subjects: 48
Study 9316778 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPNET screening
Number of subjects: 5037
Study 9316778 — intervention group
Group type: COMPARATOR
Intervention: Manual screening
Number of subjects: 5037
Study 9316778 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPNET screening (post-review)
Number of subjects: 5037
Study 9316778 — intervention group
Group type: COMPARATOR
Intervention: Manual screening (post-review)
Number of subjects: 5037
Study 9316778 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPNET screening with specific triage protocol
Number of subjects: 5037
Study 8222172 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD)
Number of subjects: 8
Study 3949375 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem monotherapy for 8 weeks
Number of subjects: 18
Study 3949375 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem therapy in subjects with pretreatment glomerular filtration rates of 80 ml/min/1.73 m2 or less
Number of subjects: 18
Study 3124898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception threshold measured with a biothesiometer in diabetic patients
Number of subjects: 174
Study 3124898 — intervention group
Group type: COMPARATOR
Intervention: Vibration perception threshold measured with a biothesiometer in non-diabetic subjects
Number of subjects: 174
Study 3124898 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 174
Study 31209428 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin with chemotherapy
Number of subjects: 101
Study 31209428 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without goserelin
Number of subjects: 101
Study 28499368 — intervention group
Group type: EXPERIMENTAL
Intervention: Warwick-Edinburgh Mental Well-being Scale (WEMWBS)
Number of subjects: 1168
Study 28499368 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)
Number of subjects: 1168
Study 28499368 — intervention group
Group type: EXPERIMENTAL
Intervention: WEMWBS and SWEMWBS
Number of subjects: 1168
Study 26281052 — intervention group
Group type: EXPERIMENTAL
Intervention: FESS associated with inferior turbinate lateral fracture and radiofrequency ablation treatment
Number of subjects: 54
Study 26281052 — intervention group
Group type: COMPARATOR
Intervention: FESS associated with inferior turbinate lateral fracture treatment
Number of subjects: 54
Study 23374902 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group intervention
Number of subjects: 71
Study 21455643 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 21455643 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study 18005926 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent distractors
Number of subjects: 0
Study 18005926 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent distractors
Number of subjects: 0
Study 18005926 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral distractors
Number of subjects: 0
Study 18005926 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study 18005926 — intervention group
Group type: EXPERIMENTAL
Intervention: Response durations
Number of subjects: 0
Study 17225672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimoraic foot boundary
Number of subjects: 0
Study 17225672 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory V-to-V effects
Number of subjects: 0
Study 17225672 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot constraint
Number of subjects: 0
Study 17225672 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiosyncratic variation across speakers
Number of subjects: 0
Study 12859126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality center-based care (full-day care, 50 weeks per year) for > 400 days
Number of subjects: 1082
Study 12859126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality center-based care for heavier LBW infants (2,001-2,500 g) for > 400 days
Number of subjects: 1082
Study 12859126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality center-based care for lighter LBW infants (<= 2,000 g) for > 400 days
Number of subjects: 1082
Study 12859126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality center-based care for > 350 days
Number of subjects: 1082
Study 11063475 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting a diet providing 28% of energy from total fat, <8% from saturated fat, </=9% from polyunsaturated fat, and <0.018 mg cholesterol*kJ(‐)(1)*d(‐)(1) (not to exceed 150 mg/d)
Number of subjects: 663
Study 11063475 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 663
Study 11063475 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention vs usual care
Number of subjects: 663
Study 11063475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 663
Study 9111818 — intervention group
Group type: EXPERIMENTAL
Intervention: JM‐13 staining in psoriasis
Number of subjects: 0
Study 9111818 — intervention group
Group type: COMPARATOR
Intervention: JM‐13 staining in uninvolved and normal skin
Number of subjects: 0
Study 9111818 — intervention group
Group type: EXPERIMENTAL
Intervention: JM‐403 staining in all specimens
Number of subjects: 0
Study 9111818 — intervention group
Group type: COMPARATOR
Intervention: JM‐403 staining in normal skin
Number of subjects: 0
Study 9111818 — intervention group
Group type: COMPARATOR
Intervention: JM‐403 staining in uninvolved skin
Number of subjects: 0
Study 9111818 — intervention group
Group type: EXPERIMENTAL
Intervention: JM‐403 staining in psoriatic skin
Number of subjects: 0
Study 9111818 — intervention group
Group type: EXPERIMENTAL
Intervention: JM‐72 staining in all biopsies
Number of subjects: 0
Study 1606981 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 60
Study 1606981 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 60
Study 4036631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg (NZ)
Number of subjects: 32
Study 4036631 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg (TZ)
Number of subjects: 32
Study 4036631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 4036631 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg (DZ)
Number of subjects: 32
Study 4036631 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg (AZ)
Number of subjects: 32
Study 30141292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at proximal and distal acupoints combined with NMES (20 min), oral function training (30 min), scalp acupuncture (1 h), body acupuncture (30 min), pricking blood at Jinjin and Yuye for patients of grade Ⅴ in TDS, treatment for 3 courses, 30 days, 5 times a week, once a day.
Number of subjects: 124
Study 30141292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at proximal and distal acupoints combined with NMES (20 min), oral function training (30 min).
Number of subjects: 124
Study 30141292 — intervention group
Group type: COMPARATOR
Intervention: Control group received NMES (20 min) and oral function training (30 min).
Number of subjects: 124
Study 27010558 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling (MUS) surgery
Number of subjects: 236
Study 24326812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS) - 1.0 mL administered to one half of the sockets
Number of subjects: 50
Study 24326812 — intervention group
Group type: COMPARATOR
Intervention: Physiological serum - 1.0 mL irrigated in the control half of the sockets
Number of subjects: 50
Study 23030566 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions combined with information consistent with health literacy level (Experiment 1)
Number of subjects: 172
Study 23030566 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions tailored to both health literacy and learning style preferences (Experiment 2)
Number of subjects: 172
Study 23030566 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge instructions (Control group in Experiment 1)
Number of subjects: 172
Study 23030566 — intervention group
Group type: COMPARATOR
Intervention: Information customized for health literacy level only (Control group in Experiment 2)
Number of subjects: 172
Study 19959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 7
Study 19959271 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 7
Study 17901958 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD) tool
Number of subjects: 56
Study 17901958 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced radiologists (R1, R2)
Number of subjects: 56
Study 17901958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced radiologists (R3, R4)
Number of subjects: 56
Study 17901958 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD
Number of subjects: 56
Study 17901958 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced readers (R1, R2)
Number of subjects: 56
Study 17901958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced readers (R3, R4)
Number of subjects: 56
Study 17901958 — intervention group
Group type: COMPARATOR
Intervention: Experienced vs inexperienced readers
Number of subjects: 56
Study 16870970 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based case management
Number of subjects: 137
Study 16870970 — intervention group
Group type: COMPARATOR
Intervention: Regular case management
Number of subjects: 137
Study 12494164 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 51
Study 12494164 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (diuretics and ACE inhibitors or ARBs)
Number of subjects: 51
Study 9922681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a topical and a systemic antibiotic
Number of subjects: 5639
Study 9922681 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial preparation
Number of subjects: 5639
Study 8526833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lake Louise AMS self‐report questionnaire
Number of subjects: 9
Study 8526833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hackett AMS questionnaire
Number of subjects: 9
Study 8526833 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Symptoms Questionnaire ESQ II
Number of subjects: 9
Study 8526833 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Symptoms Questionnaire ESQ IV
Number of subjects: 9
Study 8526833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lake Louise AMS clinical assessment score
Number of subjects: 9
Study 8526833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lake Louise functional score
Number of subjects: 9
Study 2081171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of piperacillin 30 minutes before the operation
Number of subjects: 181
Study 2081171 — intervention group
Group type: COMPARATOR
Intervention: 4 g of piperacillin 30 minutes before the operation
Number of subjects: 181
Study 6781794 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of enantate testosterone and valerianate estradiol
Number of subjects: 25
Study 6781794 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 25
Study 29813149 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral vitamin D3 supplementation of 1200 IU
Number of subjects: 975
Study 29813149 — intervention group
Group type: COMPARATOR
Intervention: Daily oral vitamin D3 supplementation of 400 IU
Number of subjects: 975
Study 27814853 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy protocol with emphasis on techniques of joint mobilization and soft-tissue management
Number of subjects: 16
Study 27814853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 24469611 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐session social learning and cognitive-behavioral treatment (N=100)
Number of subjects: 200
Study 24469611 — intervention group
Group type: COMPARATOR
Intervention: 3‐session educational intervention controlling for time and attention (N=100)
Number of subjects: 200
Study 22484579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg through a nasogastric tube 30 minutes before induction of anesthesia)
Number of subjects: 50
Study 22484579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 50
Study 22484579 — intervention group
Group type: COMPARATOR
Intervention: Control (10 mL normal saline)
Number of subjects: 50
Study 22484579 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 20537493 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1005
Study 20537493 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1005
Study 17630161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 76
Study 17630161 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 76
Study 15452587 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR50(Delta502-505) deletion variant in female subjects with BPAD
Number of subjects: 264
Study 15452587 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR50(Delta502-505) deletion variant in female subjects with MDD
Number of subjects: 264
Study 15452587 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP in exon 2 in female subjects with MDD
Number of subjects: 264
Study 15452587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intronic SNP in female subjects with SCZ
Number of subjects: 264
Study 12106829 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 61
Study 12106829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61